Clinical trial NCT05998213: Transfer of Feces in Ulcerative Colitis 2
Official title: Transfer of Feces in Ulcerative Colitis 2; Improving Efficacy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Ulcerative Colitis
Ulcerative Colitis Flare
Ulcerative Colitis Acute
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor class: OTHER
Collaborators: name: University Medical Center Groningen
name: UMC Utrecht
First posted: 2023-08-18
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this placebo-controlled randomised multicenter trial is to evaluate the efficacy and safety of anaerobic prepared donor fecal microbiota transplantation (FMT) compared to autologous FMT in patient with ulcerative colitis.

Participants will receive 4 treatments with frozen FMT via both upper and lower gastro-intestinal route (infusion via duodenal tube and enemas).

Donors are selected based on microbiota profile.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 and \<70
* Ability to give informed consent
* Established ulcerative colitis with known involvement of the left colon according to the Lennard-Jones criteria
* Partial mayo score of ≥ 3 and calprotectin \> 250
* Full Mayo score 5-9
* Endoscopic Mayo score of ≥2 in either the rectum or sigmoid upon screening sigmoidoscopy
* Stable dose of thiopurines or , 5-ASA, or budesonide in preceding 8 weeks.
* Stable dose of budesonide in preceding 2 weeks.
* Prednisone use ≤15mg/day in preceding 2 weeks with a mandatory taper of 5 mg per week starting from week 4.
* Women need to use reliable contraceptives during participation in the study
* Alkaline phosphatase \> 1.5 x ULN in the subgroup of PSC/UC patients.

Exclusion Criteria:

* Condition leading to profound immunosuppression

  * For example: HIV, infectious diseases leading to immunosuppression, bone marrow malignancies
  * Use of systemic chemotherapy
  * Child-Pugh B liver cirrhosis
* Anti-TNFα treatment in preceding 2 months
* Vedolizumab treatment in preceding 2 months
* Tofacitinib treatment in preceding 2 months
* Ustekinumab treatment in preceding 2 months
* Cyclosporine treatment in preceding 4 weeks
* Use of Methotrexate in preceding 2 months
* Prednisolone dose \> 15 mg/day in preceding 2 weeks
* Use of topical therapy in preceding 2 weeks
* Life expectancy \< 12 months
* Difficulty with swallowing
* Use of systemic antibiotics in preceding 4 weeks
* Use of probiotic treatment in preceding 4 weeks
* Positive stool cultures for common enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic e coli)
* Positive C. Difficile stool test
* Positive dual faeces test for pathogenic parasites e.g. Dientamoeba histolytica, Giardia Lamblia, Dientamoeba fragilis, Blastocystis hominis only if microscopically many or very many blastocysts are seen.
* Positive serological test for HIV
* History of surgery:

  * presence of a pouch
  * presence of stoma
* Known intra-abdominal fistula
* Pregnancy or women who give breastfeeding
* Vasopressive medication, icu stay
* Signs of ileus, diminished passage
* Allergy to macrogol or substituents, eg peanuts, shellfish
* Known allergy to iv gadolinium in the subgroup of patients who would be scheduled for MRI liver
* Crohn's disease
* Subject who has any conditions that in the opinion of the investigator, would compromise the safety of the subject or the quality of the data and is an unsuitable candidate for the study

Primary outcomes:
measure: Clinical and endoscopic remission
timeFrame: week 8
Secondary outcomes:
measure: Clinical response
timeFrame: week 8
measure: Endoscopic response, evaluated by sigmoidoscopy
timeFrame: week 8
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Amsterdam University Medical Center
state: Noord-Holland
Study officials:
References: